Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Vincent J NijenhuisJorn BrouwerRonak DelewiRenicus S HermanidesWouter HolvoetChristophe L F DuboisPeter FrambachBernard De BruyneGert K van HouwelingenJan A S Van Der HeydenPetr ToušekFrank van der KleyIan BuysschaertCarl E SchotborghBert FerdinandePim van der HarstJohn RoosenJoyce PeperFrederick W F ThielenLeo VeenstraDean R P P Chan Pin YinMartin J SwaansBenno J W M RensingArnoud W J van 't HofLeo TimmersJohannes C KelderPieter R StellaJan BaanJurriën M Ten BergPublished in: The New England journal of medicine (2020)
In patients undergoing TAVI who were receiving oral anticoagulation, the incidence of serious bleeding over a period of 1 month or 1 year was lower with oral anticoagulation alone than with oral anticoagulation plus clopidogrel. (Funded by the Netherlands Organization for Health Research and Development; POPular TAVI EU Clinical Trials Register number, 2013-003125-28; ClinicalTrials.gov number, NCT02247128.).
Keyphrases
- transcatheter aortic valve implantation
- atrial fibrillation
- aortic valve
- venous thromboembolism
- aortic stenosis
- aortic valve replacement
- patients undergoing
- clinical trial
- acute coronary syndrome
- percutaneous coronary intervention
- transcatheter aortic valve replacement
- antiplatelet therapy
- heart failure
- ejection fraction
- risk factors
- left ventricular
- randomized controlled trial
- open label
- study protocol